好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

The Combined Impact of Intravenous Thrombolysis and Transfer Strategy on Endovascular Thrombectomy Outcomes for Vertebrobasilar Artery Occlusions
Cerebrovascular Disease and Interventional Neurology
P12 - Poster Session 12 (11:45 AM-12:45 PM)
13-001

To investigate the interaction between intravenous thrombolysis (IVT) and transfer strategies (mothership vs. transfer) on outcomes following endovascular thrombectomy (EVT) for vertebrobasilar artery occlusions (VBAOs).

EVT has become a standard intervention for acute ischemic stroke caused by VBAOs.

A retrospective analysis was conducted on VBAO patients who underwent EVT. Patients were categorized based on treatment type: IVT followed by EVT or EVT alone. Transfer strategies were classified as mothership or transfer. The primary outcomes were modified Rankin Scale (mRS≤3) and mortality at 90 days.

Among 175 patients, the median age was 67 years with 54.9% males. Among these, 33 patients (18.9%) received IVT before EVT, while 142 (81.1%) underwent EVT alone. Among all patients, 48 (27.4%) presented as mothership, and 127 (72.6%) were transfers. In bridging IVT cohort, mRS≤ 3 at 90 days was observed in 58.3% of the mothership group, a higher rate compared to 38.9% in the transfer group. For EVT alone cohort, the mothership group demonstrated a lower rate of mRS≤ 3 at 90 days (35.3%) compared to transfer (45.8%). The mothership group in the IVT cohort had a 90-day mortality rate of 41.7% compared to 50.0% in the transfer group, while for patients undergoing EVT alone, the mothership group had a mortality rate of 52.9% versus 43.8% in the transfer group. Interaction analysis indicated that the mothership strategy may have more pronounced benefits for IVT-refractory patients; however, the overall interaction effect was not statistically significant (p>0.05).

 

In patients with VBAOs undergoing EVT, bridging IVT showed better clinical outcomes in the mothership group compared to those transferred from outside hospitals, particularly in contrast to the EVT-alone group. These findings suggest that the mothership strategy may benefit patients who are potentially IVT-refractory. Further studies with larger sample sizes are needed to confirm these results.

Authors/Disclosures
Lucas Rios Rocha, MD (UPMC)
PRESENTER
Dr. Rios Rocha has nothing to disclose.
Mohamed Fahmy Doheim (University of Pittsburgh) Mr. Doheim has nothing to disclose.
Abdullah M. Al-Qudah, MD (University of Pittsburgh Medical Center) Dr. Al-Qudah has nothing to disclose.
Anmol Almast Miss Almast has nothing to disclose.
Matthew T. Starr, MD (University of Pittsburgh Medical Center) Dr. Starr has nothing to disclose.
Marcelo Rocha, MD, PhD (UPMC) The institution of Dr. Rocha has received research support from NIH.
Nirav Bhatt, MD (University of Pittsburgh) Dr. Bhatt has nothing to disclose.
Jussie Correia Lima, MD Dr. Correia Lima has nothing to disclose.
Bradley Gross, MD Dr. Gross has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Medtronic. Dr. Gross has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Microvention. Dr. Gross has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AHA.
Michael Lang, MD Dr. Lang has nothing to disclose.
Raul G. Nogueira, MD (UPMC Stroke Institute) Dr. Nogueira has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for for advisory roles with Anaconda, Biogen, Cerenovus, Genentech, Hybernia, Imperative Care, Medtronic, Phenox, Philips, Prolong Pharmaceuticals, Stryker Neurovascular, Shanghai Wallaby, and Synchron (consulting fees) as well as for advisory roles with Astrocyte, Brainomix, Cerebrotech, Ceretrieve, Corindus Vascular Robotics, Vesalio, Viz-AI, RapidPulse and Perfuze ( stock options). Dr. Nogueira has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Law Firms. Dr. Nogueira has received stock or an ownership interest from Viz-AI, Perfuze, Cerebrotech, Reist/Q'Apel Medical, Truvic, and Viseon. The institution of Dr. Nogueira has received research support from Cerenovus.
Alhamza Al-Bayati, MD (UPMC Stroke Institute) Dr. Al-Bayati has nothing to disclose.